Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

ABSTRACT:

Background

The discovery of potent and broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) has made passive immunization a potential strategy for the prevention and treatment of HIV infection. We sought to determine whether passive administration of VRC01, a bNAb targeting the HIV CD4-binding site, can safely prevent or delay plasma viral rebound after the discontinuation of antiretroviral therapy (ART).

Methods

We conducted two open-label trials (AIDS Clinical Trials Group [ACTG] A5340 and National Institutes of Health [NIH] 15-I-0140) of the safety, side-effect profile, pharmacokinetic properties, and antiviral activity of VRC01 in persons with HIV infection who were undergoing interruption of ART.

Results

A total of 24 participants we

SUBMITTER: Bar KJ 

PROVIDER: S-EPMC5292134 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature